The surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in the EU/EEA is essential for detecting emerging and increasing antimicrobial resistance. Since 2009, this surveillance has been co-ordinated by the European Centre for Disease Prevention and Control (ECDC).
This framework describes the building blocks and actions that ECDC will use to support and EU/EEA countries and the European Commission to achieve the Sustainable Development Goal (SDG).
This report presents the results of the first external quality assurance (EQA) scheme for B. pertussis antimicrobial susceptibility testing by ECDC as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) consortium.
This framework describes the building blocks being laid down by the European Centre for Disease Prevention and Control (ECDC) to support and empower European Union (EU)/European Economic Area (EEA) countries and the European Commission in achieving microbial safety for substances of human origin (SoHO).
The results of this external quality assurance distribution have shown that European Haemophilus reference laboratories differ in the level of characterisation of strains, ranging from simple speciation to full identification and typing. All but two laboratories routinely phenotypically serotype isolates. Fifteen laboratories (52%) performed PCR-based capsular genotyping, 23 laboratories (79%) reported antimicrobial susceptibility testing results.